The value of other angiogenic and inflammatory biomarkers, such as placental growth factor (PlGF) [80], VEGF-A, IL-6 [58], IL-12 [80], and tumor necrosis factor-α (TNF-α) [58], seemed to best discriminate SSc patients who were on the verge of developing PAH. The gene discussed is VEGFA; the disease is systemic sclerosis.